Evidence of reduced ADAMTS13 activity in the presence of schistocytes (~ 2–4%) appeared compatible with thrombotic microangiopathy (TMA) secondary to COVID-19 [34]. This evidence concerns the gene ADAMTS13 and COVID-19.